Kamada (NASDAQ: KMDA) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Valuation & Earnings

This table compares Kamada and Fortress Biotech’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kamada $77.49 million 2.45 -$6.73 million ($0.04) -117.47
Fortress Biotech $16.48 million 12.33 -$55.09 million ($1.83) -2.19

Kamada has higher revenue and earnings than Fortress Biotech. Kamada is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

6.3% of Kamada shares are owned by institutional investors. Comparatively, 12.1% of Fortress Biotech shares are owned by institutional investors. 33.3% of Fortress Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Kamada and Fortress Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kamada -1.27% -1.64% -1.14%
Fortress Biotech -65.80% -61.43% -33.68%

Risk and Volatility

Kamada has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Kamada and Fortress Biotech, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kamada 0 0 2 0 3.00
Fortress Biotech 0 0 4 0 3.00

Kamada currently has a consensus target price of $8.50, suggesting a potential upside of 80.85%. Fortress Biotech has a consensus target price of $11.00, suggesting a potential upside of 174.31%. Given Fortress Biotech’s higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Kamada.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Fortress Biotech Company Profile

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.